Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05614024 · ClinicalTrials.gov registry record · NA

Neurofeedback During Eating for Bulimia Nervosa

A NA study of Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05614024 is a NA study of Bulimia Nervosa that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 1,737-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05614024, a NA study of Bulimia Nervosa, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.

Conditions Studied

Interventions

  • OTHER Real fNIRS Neurofeedback
  • OTHER Sham-Control fNIRS Neurofeedback

Study Locations (1)

New York

  • Center for Computational Psychiatry at the Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-05-13
Est. Completion 2027-12
Phase NA

What the Registry Record Tells You About NCT05614024

The ClinicalTrials.gov registry entry for NCT05614024 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,737-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (98% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bulimia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Real fNIRS Neurofeedback is the first listed.

NCT05614024 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05614024 about?

NCT05614024 is a clinical study titled "Neurofeedback During Eating for Bulimia Nervosa". The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influen...

What is the current status of trial NCT05614024?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-05-13. Estimated completion is 2027-12.

What conditions does trial NCT05614024 study?

This clinical trial studies the following conditions: Bulimia Nervosa.

What interventions are being tested in trial NCT05614024?

The interventions under investigation include: Real fNIRS Neurofeedback (OTHER), Sham-Control fNIRS Neurofeedback (OTHER).

Who is sponsoring clinical trial NCT05614024?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05614024 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bulimia Nervosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.